Press realease : BiOkuris strengthens exclusive partnership with Apriwell for BK001(Novacalm®) and expands reach to Austria and Luxembourg
December 02, 2024 – Liège, Belgium and Berlin, Germany – BiOkuris, a leader in gastrointestinal health solutions, has strengthened its partnership with Apriwell through a new exclusive agreement covering online sales of Novacalm® (BK001) in Germany, Austria, and Luxembourg. This agreement not only strengthens Apriwell’s partnership to exclusive online rights for Novacalm® in Germany but also expands BiOkuris’ reach to Austria and Luxembourg, positioning both companies to address a growing demand for effective digestive health solutions across these markets. In these countries, BK001 is marketed under the brand name Novacalm®, as part of a private labeling strategy.
This expansion builds on Novacalm®’s strong performance in Germany, where it has gained significant traction among consumers seeking relief from gastrointestinal issues. By extending into Austria and Luxembourg, BiOkuris aims to replicate Novacalm®’s success in countries with high rates of digestive health challenges. Gastrointestinal conditions affect approximately 16.6% of adults in Germany, with around 1.1 million individuals diagnosed with irritable bowel syndrome and an estimated 64.9 million episodes of acute gastrointestinal illness occurring annually. Similar prevalence rates are likely in Austria and Luxembourg, emphasizing the urgent need for effective digestive health solutions. Products like Novacalm® are uniquely positioned to meet this urgent market need.With this growing demand, BiOkuris expects significant revenue growth in the coming years as Novacalm®’s reach expands through Apriwell’s exclusive online distribution channels.
François Blondel, CEO and Chairman of the Board at BiOkuris, commented on the expanded collaboration: “Our partnership with Apriwell has proven highly successful in Germany, making this expansion into Austria and Luxembourg a natural next step. The exclusivity granted to Apriwell reflects the strength of our collaboration and the substantial value we are delivering to patients.”
Alexander Puschilov, CEO of Apriwell, added, “This extended partnership with BiOkuris underscores our long-term commitment to advancing patient care in gastrointestinal health. Novacalm® has performed exceptionally well in Germany, and we are thrilled to bring this trusted solution to Austria and Luxembourg. This expansion is a clear indicator of the product’s success and our shared vision for growth in the region.”
This exclusive agreement further solidifies BiOkuris and Apriwell’s positions in the European gastrointestinal health market, with high expectations for increased patient reach and revenue growth over the coming years.
- Häuser et al., Dtsch Arztebl Int 2019; 116: 463-70. DOI: 10.3238/arztebl.2019.0463
- Wilking et al., Epidemiology & Infection , Volume 141 , Issue 11 , November 2013 , pp. 2365 – 2375.